Trials / Conditions / Relapsed Pediatric AML
Relapsed Pediatric AML
6 registered clinical trials studyying Relapsed Pediatric AML — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Withdrawn | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML NCT05622591 | Elucida Oncology | Phase 1 |
| Unknown | TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia NCT04033627 | Shanghai Children's Medical Center | N/A |
| Recruiting | Vyxeos® With Clofarabine for Pediatric AML NCT07156435 | Princess Maxima Center for Pediatric Oncology | Phase 1 |
| Completed | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia NCT04562792 | Children's Mercy Hospital Kansas City | Phase 2 |
| Unknown | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy NCT02638428 | Samsung Medical Center | Phase 2 |
| Approved For Marketing | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation NCT03245424 | Agios Pharmaceuticals, Inc. | — |